Zalutumumab
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Cancer
Conditions
Head and Neck Cancer, Squamous Cell Cancer
Trial Timeline
Nov 1, 2006 → Aug 1, 2011
NCT ID
NCT00382031About Zalutumumab
Zalutumumab is a phase 3 stage product being developed by Genmab for Head and Neck Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00382031. Target conditions include Head and Neck Cancer, Squamous Cell Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01449357 | Phase 2 | Withdrawn |
| NCT01054625 | Phase 1/2 | Completed |
| NCT00707655 | Phase 1/2 | Terminated |
| NCT00677924 | Phase 1/2 | Terminated |
| NCT00542308 | Phase 2 | Completed |
| NCT00382031 | Phase 3 | Completed |
| NCT00093041 | Phase 1/2 | Completed |
Competing Products
20 competing products in Head and Neck Cancer